Sugar, Invert
drug drugOn this page
Also known as C0171Corn invert sugarCorn invert sugar syrupInsubetaInvert sugarInvertoseLipoderma aaMaize invert sugarNulomolineSaccharide hydrolysateTravertUnimoist u-125SUGARINVERT
Summary
Sugar, Invert (CHEMBL1201647) is an approved unknown (ATC C05BB03); indicated across 1 condition including varicose disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: C05BB03
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201647 |
| Name | Sugar, Invert |
| Type | Unknown |
| Max phase | 4 |
| ATC | C05BB03 |
Also known as: C0171, Corn invert sugar, Corn invert sugar syrup, Insubeta, Invert sugar, Invertose, Lipoderma aa, Maize invert sugar, Nulomoline, Saccharide hydrolysate, Travert, Unimoist u-125
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| varicose disease | 4 | MONDO:0008638 | HP:0002619 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: varicose disease